← Back to Search

Employment-Based Abstinence Reinforcement for Opioid Use Disorder

N/A

Recruiting

Led By Kenneth Silverman, PhD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 weeks

Awards & highlights

Study Summary

This trial seeks to develop a low-cost Therapeutic Workplace that community drug abuse treatment programs can implement to address opioid addiction & poverty.

Who is the study for?

This trial is for adults over 18 who are unemployed, have opioid use disorder, and are receiving methadone or buprenorphine treatment at REACH. It's not open to prisoners or those experiencing recent hallucinations.Check my eligibility

What is being tested?

The study tests a 'Therapeutic Workplace' where participants earn wages while staying drug-free. They're randomly assigned to different groups with varying levels of wage incentives tied to providing clean urine samples.See study design

What are the potential side effects?

Since the intervention involves employment and financial incentives rather than medication, there aren't direct medical side effects; however, stress or anxiety related to maintaining abstinence for financial reward could occur.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rate of Drug abstinence as assessed by a yes or no

Rate of Employment as assessed by a yes or no

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Initiation and Maintenance groupExperimental Treatment1 Intervention

The Initiation and Maintenance group procedures will receive the same intervention as the Initiation Only participants for 24 weeks (during the Initiation period). Then, Initiation and Maintenance participants will receive a low-magnitude incentive intervention for 52 weeks (the Maintenance period, weeks 25-76) to maintain drug abstinence and employment. The low-magnitude incentive intervention will be identical to the final weeks of the high magnitude incentive intervention, with two important exceptions. During the low-magnitude intervention, participants will receive money per hour for maintaining drug abstinence and work (stipends for working with the employment specialist and wage supplements for providing pay stubs). During weeks 25-76, if a participant in the Initiation and Maintenance group provides a drug-positive urine sample or misses a required mandatory sample, the participant will not receive any incentive.

Group II: Initiation Only groupExperimental Treatment1 Intervention

Participants assigned to the Initiation Only group will be able to earn abstinence-contingent stipends for working with the employment specialist for up to 20 hours per week and performance stipends for engaging in job-seeking behaviors. When employed, those participants will be able to earn abstinence-contingent wage supplements for up to 40 hours worked (verified by pay stubs) in a community job. Participants can earn from both Therapeutic Workplace Work Hours and from wage supplements for working in a community job, however, participants will only be able to earn stipends and wage supplements for a maximum total of 40 hours.

Group III: Usual Care Control groupActive Control1 Intervention

Participants in the Usual Care Control group will receive methadone or buprenorphine treatment, counseling, and employment services.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor

2,263 Previous Clinical Trials

14,822,940 Total Patients Enrolled

National Institute on Drug Abuse (NIDA)NIH

2,469 Previous Clinical Trials

2,619,184 Total Patients Enrolled

Kenneth Silverman, PhDPrincipal InvestigatorJohns Hopkins University

3 Previous Clinical Trials

349 Total Patients Enrolled

Media Library

Employment-based abstinence reinforcement Clinical Trial Eligibility Overview. Trial Name: NCT05534815 — N/A

Substance Addiction Research Study Groups: Usual Care Control group, Initiation Only group, Initiation and Maintenance group

Substance Addiction Clinical Trial 2023: Employment-based abstinence reinforcement Highlights & Side Effects. Trial Name: NCT05534815 — N/A

Employment-based abstinence reinforcement 2023 Treatment Timeline for Medical Study. Trial Name: NCT05534815 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many subjects are being treated as part of this medical experiment?

"Affirmative. Per the information posted on clinicaltrials.gov, this research project is presently recruiting participants. It was initially advertised on March 1st 2023 and modified more recently on September 3rd 2023. There are 225 spots available for individuals at a single testing site."

Answered by AI

Are there any openings in this clinical trial currently being accepted?

"Affirmative. Clinicaltrials.gov has reported that this clinical trial, which was initially posted on the 1st of March 2023, is currently recruiting participants. 225 people are needed at one medical centre to complete the study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Long-Term Treatment of Opioid Use Disorder

2023. "Long-Term Treatment of Opioid Use Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05534815.